Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Centocor’s Remicade Gains Pediatric Crohn’s Disease Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Remicade is the first Crohn's disease therapy approved for pediatric patients following its May 19 supplemental BLA approval

You may also be interested in...



Humira Clears FDA As First Self-Administered Biologic For Crohn’s Disease

Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.

Humira Clears FDA As First Self-Administered Biologic For Crohn’s Disease

Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.

J&J/Centocor Seek To Expand Remicade Psoriatic Arthritis Indication

sBLA for the arthritis medication seeks to add inhibition of disease progression to labeling.

Related Content

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel